Free Trial
NYSE:BVS

Bioventus 3/12/2024 Earnings Report

Bioventus logo
$7.34 +0.08 (+1.10%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$7.06 -0.29 (-3.88%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bioventus EPS Results

Actual EPS
$0.07
Consensus EPS
$0.06
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Bioventus Revenue Results

Actual Revenue
$135.42 million
Expected Revenue
$124.84 million
Beat/Miss
Beat by +$10.58 million
YoY Revenue Growth
N/A

Bioventus Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Conference Call Audio

Earnings Conference Call
Bioventus
00:00 / 00:00

Bioventus Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Bioventus Shares Rise After Improved 4Q
Bioventus reports Q4 non-GAAP EPS 15c, consensus 8c
See More Bioventus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioventus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioventus and other key companies, straight to your email.

About Bioventus

Bioventus (NYSE:BVS), a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

View Bioventus Profile

More Earnings Resources from MarketBeat